Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1994 Feb;71(2):166–169. doi: 10.1136/hrt.71.2.166

Impaired left ventricular filling rate induced by treatment with recombinant interleukin 2 for advanced cancer.

G Fragasso 1, M Tresoldi 1, R Benti 1, M Vidal 1, M Marcatti 1, A Borri 1, C Besana 1, P P Gerundini 1, C Rugarli 1, S Chierchia 1
PMCID: PMC483638  PMID: 8130026

Abstract

BACKGROUND--Immunotherapy with recombinant interleukin 2 (rIL 2) has been extensively used to treat cancer but its use has been hampered by serious side effects including severe hypotension, arrhythmias, and myocardial infarction. OBJECTIVE--To assess the effects of rIL 2 on human left ventricular function. METHODS--Left ventricular (LV) function was monitored in 22 patients (9 women, 13 men) (mean (SD) age 53 (10) years) undergoing a 120 h continuous intravenous infusion of rIL 2 (18 x 10(6) IU/m2/day) for melanoma (4), renal cell (16), ovarian (1), and colon cancer (1). Radionuclide ventriculography was performed before and 1 h after the end of treatment. Ejection fraction (EF), peak emptying rate (PER), peak filling rate (PFR), and regional left ventricular wall motion were analysed. Heart rate (HR), central venous pressure (CVP), systolic (SBP) and diastolic blood pressures (DBP), the electrocardiogram, and myocardial enzyme concentrations were monitored throughout the study. RESULTS--All variables (mean (SD)) were normal before rIL 2 was given. After rIL 2 administration HR increased significantly from 84 (11) to 125 (18) beats/min (p < 0.0001), SBP fell from 128 (11) to 100 (9) mmHg (p < 0.001) and DBP from 76 (9) to 65 (7) mmHg (p < 0.0001). CVP decreased from 3.70 (3.2) to 1.30 (0.45) cm H2O (p < 0.001). EF (65 (7) to 64 (8%) and PER (3.56 (0.60) to 3.86 (0.83) EDV/s) did not change significantly. PFR decreased significantly at the end of the rIL 2 infusion from 2.68 (0.46) to 2.37 (0.43) EDV/s (p < 0.01). Left ventricular segmental hypokinesia developed in 6 patients. Myocardial enzyme concentrations remained normal throughout the study. CONCLUSIONS--The results of this study confirmed that rIL 2 produces important haemodynamic changes, predominantly related to decreased systemic resistance. However, the observed reduction in PFR in most patients suggested that rIL 2 might exert its action at the level of the heart muscle itself. The localised systolic dysfunction in some patients suggested that rIL 2 might also adversely affect myocardial perfusion.

Full text

PDF
166

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  2. Chierchia S., Brunelli C., Simonetti I., Lazzari M., Maseri A. Sequence of events in angina at rest: primary reduction in coronary flow. Circulation. 1980 Apr;61(4):759–768. doi: 10.1161/01.cir.61.4.759. [DOI] [PubMed] [Google Scholar]
  3. Chung M. K., Gulick T. S., Rotondo R. E., Schreiner G. F., Lange L. G. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res. 1990 Sep;67(3):753–763. doi: 10.1161/01.res.67.3.753. [DOI] [PubMed] [Google Scholar]
  4. Davies G. J., Bencivelli W., Fragasso G., Chierchia S., Crea F., Crow J., Crean P. A., Pratt T., Morgan M., Maseri A. Sequence and magnitude of ventricular volume changes in painful and painless myocardial ischemia. Circulation. 1988 Aug;78(2):310–319. doi: 10.1161/01.cir.78.2.310. [DOI] [PubMed] [Google Scholar]
  5. Finkel M. S., Oddis C. V., Jacob T. D., Watkins S. C., Hattler B. G., Simmons R. L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992 Jul 17;257(5068):387–389. doi: 10.1126/science.1631560. [DOI] [PubMed] [Google Scholar]
  6. Gaynor E. R., Vitek L., Sticklin L., Creekmore S. P., Ferraro M. E., Thomas J. X., Jr, Fisher S. G., Fisher R. I. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1988 Dec 15;109(12):953–958. doi: 10.7326/0003-4819-109-12-953. [DOI] [PubMed] [Google Scholar]
  7. Gulick T., Chung M. K., Pieper S. J., Schreiner G. F., Lange L. G. Immune cytokine inhibition of beta-adrenergic agonist stimulated cyclic AMP generation in cardiac myocytes. Biochem Biophys Res Commun. 1988 Jan 15;150(1):1–9. doi: 10.1016/0006-291x(88)90478-0. [DOI] [PubMed] [Google Scholar]
  8. Hess M. L., Hastillo A., Greenfield L. J. Spectrum of cardiovascular function during gram-negative sepsis. Prog Cardiovasc Dis. 1981 Jan-Feb;23(4):279–298. doi: 10.1016/0033-0620(81)90017-7. [DOI] [PubMed] [Google Scholar]
  9. Hesse D. G., Tracey K. J., Fong Y., Manogue K. R., Palladino M. A., Jr, Cerami A., Shires G. T., Lowry S. F. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988 Feb;166(2):147–153. [PubMed] [Google Scholar]
  10. Hibbs J. B., Jr, Westenfelder C., Taintor R., Vavrin Z., Kablitz C., Baranowski R. L., Ward J. H., Menlove R. L., McMurry M. P., Kushner J. P. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest. 1992 Mar;89(3):867–877. doi: 10.1172/JCI115666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ishida Y., Meisner J. S., Tsujioka K., Gallo J. I., Yoran C., Frater R. W., Yellin E. L. Left ventricular filling dynamics: influence of left ventricular relaxation and left atrial pressure. Circulation. 1986 Jul;74(1):187–196. doi: 10.1161/01.cir.74.1.187. [DOI] [PubMed] [Google Scholar]
  12. Isner J. M., Dietz W. A. Cardiovascular consequences of recombinant DNA technology: interleukin-2. Ann Intern Med. 1988 Dec 15;109(12):933–935. doi: 10.7326/0003-4819-109-12-933. [DOI] [PubMed] [Google Scholar]
  13. Kilbourn R. G., Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst. 1990 May 2;82(9):772–776. doi: 10.1093/jnci/82.9.772. [DOI] [PubMed] [Google Scholar]
  14. McKenna T. M. Prolonged exposure of rat aorta to low levels of endotoxin in vitro results in impaired contractility. Association with vascular cytokine release. J Clin Invest. 1990 Jul;86(1):160–168. doi: 10.1172/JCI114679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Natanson C., Eichenholz P. W., Danner R. L., Eichacker P. Q., Hoffman W. D., Kuo G. C., Banks S. M., MacVittie T. J., Parrillo J. E. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989 Mar 1;169(3):823–832. doi: 10.1084/jem.169.3.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ognibene F. P., Rosenberg S. A., Lotze M., Skibber J., Parker M. M., Shelhamer J. H., Parrillo J. E. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest. 1988 Oct;94(4):750–754. doi: 10.1378/chest.94.4.750. [DOI] [PubMed] [Google Scholar]
  17. Osanto S., Cluitmans F. H., Franks C. R., Bosker H. A., Cleton F. J. Myocardial injury after interleukin-2 therapy. Lancet. 1988 Jul 2;2(8601):48–49. doi: 10.1016/s0140-6736(88)92982-0. [DOI] [PubMed] [Google Scholar]
  18. Parker M. M., Parrillo J. E. Septic shock. Hemodynamics and pathogenesis. JAMA. 1983 Dec 23;250(24):3324–3327. [PubMed] [Google Scholar]
  19. Parratt J. R. Myocardial and circulatory effects of E. coli endotoxin; modification of responses to catecholamines. Br J Pharmacol. 1973 Jan;47(1):12–25. doi: 10.1111/j.1476-5381.1973.tb08154.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rees D. D., Cellek S., Palmer R. M., Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun. 1990 Dec 14;173(2):541–547. doi: 10.1016/s0006-291x(05)80068-3. [DOI] [PubMed] [Google Scholar]
  21. Rosenberg S. A., Lotze M. T., Mulé J. J. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med. 1988 Jun;108(6):853–864. doi: 10.7326/0003-4819-108-6-853. [DOI] [PubMed] [Google Scholar]
  22. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  23. Rosenstein M., Ettinghausen S. E., Rosenberg S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735–1742. [PubMed] [Google Scholar]
  24. SALISBURY P. F., CROSS C. E., RIEBEN P. A. Distensibility and water content of heart muscle before and after injury. Circ Res. 1960 Jul;8:788–793. doi: 10.1161/01.res.8.4.788. [DOI] [PubMed] [Google Scholar]
  25. Samlowski W. E., Ward J. H., Craven C. M., Freedman R. A. Severe myocarditis following high-dose interleukin-2 administration. Arch Pathol Lab Med. 1989 Aug;113(8):838–841. [PubMed] [Google Scholar]
  26. Thiemermann C., Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol. 1990 Jul 17;182(3):591–595. doi: 10.1016/0014-2999(90)90062-b. [DOI] [PubMed] [Google Scholar]
  27. Vaitkus P. T., Grossman D., Fox K. R., McEvoy M. D., Doherty J. U. Complete heart block due to interleukin-2 therapy. Am Heart J. 1990 Apr;119(4):978–980. doi: 10.1016/s0002-8703(05)80349-7. [DOI] [PubMed] [Google Scholar]
  28. Wakabayashi I., Hatake K., Kakishita E., Nagai K. Diminution of contractile response of the aorta from endotoxin-injected rats. Eur J Pharmacol. 1987 Sep 2;141(1):117–122. doi: 10.1016/0014-2999(87)90417-1. [DOI] [PubMed] [Google Scholar]
  29. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES